Bicara Therapeutics Inc (BCAX) has a current stock price of $10.96. During the previous trading session, the stock witnessed a notable rise, reaching a high of $48.0 after opening at $10.96. The stock’s low for the day was $8.0, and it eventually closed at $11.51.
Bicara Therapeutics Inc’s stock has had a tumultuous market performance.
52-week price history of BCAX Stock
A stock’s 52-week high and low prices can reveal a great deal about its present condition and potential future performance. Bicara Therapeutics Inc’s current trading price is -60.98% away from its 52-week high, while its distance from the 52-week low is 40.51%. The stock’s price range during this period has fluctuated between $7.80 and $28.09. Shares of the company, which operates in the Healthcare sector, recorded a trading volume of around 0.54 million for the day, which was evidently lower than the average daily volume of 0.76 million over the last three months.
Financial Performance and Market Capitalization
Bicara Therapeutics Inc (BCAX) has experienced a quarterly decline of -27.13% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 598.01M and boasts a workforce of 55 employees.
Analysts’ Ratings For Bicara Therapeutics Inc
As of right now, 4 analysts are rating Bicara Therapeutics Inc as a BUY, 3 of the polled analysts branded the stock as an OVERWEIGHT, 1 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Moving average and trading volume data
Based on Barchart.com data, the company’s moving average over the 100-day period was 11.51, with a change in price of -2.44. Similarly, Bicara Therapeutics Inc recorded 687,429 in trading volume during the last 100 days, posting a change of -18.21%.
BCAX Debt-to-equity ratio analysis
The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for BCAX stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.00.
BCAX Stock Stochastic Average
The raw stochastic average for Bicara Therapeutics Inc over the last 50 days is presently at 58.22%. This reflects a surge from the raw stochastic average of the previous 20 days, which was noted at 56.50%. Further, the company’s Stochastic %K and %D values for the last 20 days were 70.34% and 75.85%, respectively.
BCAX Stock Price Performance Analysis
The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data.
